New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 2, # 5 - September, 1996

Table of Contents

STATE-OF-THE-ART MANAGEMENT OF CANCER
BREAST CANCER­PART II
Asymptomatic Population Screening and Susceptibility Testing
Breast Self Examination 358
  Inventive Products 358
Breast Cancer Screening Based on Mammography 358
  Mammography Screening for Women Aged 40-49 Years 359
  Problems Associated with Mammography 361
  Mammography Screening Costs 361
Genetic Susceptibility Screening 361
  Susceptibility Screening in Breast Cancer 361
    Myriad Genetics 362
    OncorMed 362
    Visible Genetics 362
MEETING COVERAGE
NEW DEVELOPMENTS IN THE TREATMENT OF AIDS-ASSOCIATED KAPOSI'S SARCOMA
From the XI International AIDS Conference
Vancouver, BC, Canada - July 7-12, 1996
Epidemiology 362
Etiology 363
Pathogenesis 363
Diagnosis 364
Current Treatment Options and Novel Approaches 364
  Chemotherapy 364
    Combination chemotherapy 364
    Liposomal doxorubicin 364
    Liposomal daunorubicin 367
    Topical retinoid gel 368
    All-trans-retinoic acid 368
    Paclitaxel 368
  Radiation Therapy 368
  Photodynamic Therapy 369
    Delta-aminolaevulinic acid 369
    Tin ethyletiopurpuria 369
  Antiretroviral Therapy 369
  Hormonal Therapy 369
    Human chorionic gonadotropin 369
  Cytokine Modulation 370
ISSUES IN ONCOLOGY
RANDOMIZED CLINICAL TRIALS IN ONCOLOGY
What are oncology RCTs? 370
RCT Patient Selection and Randomization Approaches 371
  Patient Selection 371
  Statistical Considerations 371
The Impact of RCTs in Oncology 372
  Use of RCTs in Oncology is Expected to Intensify 373
Types of RCTs in Oncology 373
  RCTs in Cancer Prevention 373
  RCTs to Evaluate Screening and Diagnostic Approaches 374
  Role of RCTs in Evaluating Treatment Modalities 374
    RCTs in primary therapies 374
    RCTs in adjuvant therapies 374
    RCTs in neo-adjuvant therapies 374
  RCTs in Advanced Disease 374
  RCTs in Supportive Care 374
  New Therapeutic Technologies and RCTs 374
Surrogate Endpoints 374
Challenges in Interpreting RCTs 376
Generating Actionable Information from RCTs 376
  Clinical Meaning of RCT Results 376
Current Challenges in Conducting RCTs 377
  Costs 377
  Ethical Considerations 377
  Other Limiting Factors 377
RCT Alternatives 377
  Large, simplified RCTs (LSRCTs) 378
  Meta-Analysis 378
  Health Economic Models 379
  Monte Carlo Simulations 379

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887